← Back to Clinical Trials
Recruiting NCT07527624

NCT07527624 Evaluation of Socio-professional Inclusion for Young Adults Aged 15-25 Living With a Rare Genetic Disability

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07527624
Status Recruiting
Phase
Sponsor Imagine Institute
Condition Rare Diseases
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-01-08
Primary Completion 2026-06-08

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 25 Years
Study Type OBSERVATIONAL
Interventions
survey

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-01-08 with a primary completion date of 2026-06-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Rare diseases are often synonymous with difficulties for sufferers, whether physical, mental or social. Patients suffering from rare diseases face specific problems, such as the long wait for a diagnosis, the geographical distance between the rare disease reference center and home, and the isolation created by this very disabling disease... Children suffering from rare genetic diseases have difficulty accessing higher education, but above all in finding an internship or work-study placement, due to the rarity of their disability. The aim of this study, entitled "Imagine La Suite", is to assess the difficulties encountered by young people with rare genetic diseases and disabilities in their search for vocational and university training or employment.

Eligibility Criteria

Inclusion Criteria: * Current age 15-25 years born between 1997 and 2007 * Rare genetic disease confirmed by a genetic test, originating in childhood and followed at Necker in the networks of the following disease reference centers: * epilepsy without deficiency ; * genodermatosis ; * constitutional bone diseases ; * craniofacial malformations; * deafness; Exclusion Criteria: * Patient or parent's opposition to study participation * Patient with intellectual disability (IQ \< 70) * Patients with pathologies involving intellectual disability and patients with a clinical sign of intellectual disability.

Contact & Investigator

Central Contact

Fatima clinical project manager, Medical doctor

✉ recherche-clinique@institutimagine.org

📞 +33 (0)1 42 75 45 65

Frequently Asked Questions

Who can join the NCT07527624 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 25 Years, studying Rare Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07527624 currently recruiting?

Yes, NCT07527624 is actively recruiting participants. Contact the research team at recherche-clinique@institutimagine.org for enrollment information.

Where is the NCT07527624 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT07527624 clinical trial?

NCT07527624 is sponsored by Imagine Institute. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology